Affirm and Shopify launch Shop Pay Installments in Australia
Affirm and Shopify launch Shop Pay Installments in Australia, extending a rollout that began in Canada in 2025, as AFRM shares jump on separate earnings.
Section
Banking and Finance
The latest banking and finance news and analysis from the Financial News newsroom.
- Stories
- 1,499
- Follow
- RSS feed
All stories
401–410 of 1,499
Build-A-Bear stock slumps ~16% as revenue falls to $115.3m in Q2
Build-A-Bear quarterly earnings results show revenue down to $115.3m and EPS at $0.70, but shares fell 16% on a full-year guidance cut.
Sandisk, Kioxia unveil $31bn Japan investment plan
Sandisk and Kioxia detail a $31bn Japan investment plan through 2032, but the funding hinges on Tokyo and markets reacted with caution, not cheer.
Diageo Share Price Recovery Gains Pace as Lewis Era Begins
The Diageo share price recovery is drawing fresh attention after shares in the FTSE 100 spirits group (LSE: DGE) climbed 12.5% over the past month, the strongest run the stock…
Shell Q2 2026 Earnings Hit Near-Record as Hormuz Crisis Fuels $3bn Buyback
Shell's Q2 2026 earnings reached $9.8bn, the second-highest quarterly figure in the company's history, as disruption to oil flows through the Strait of Hormuz drove prices and trading margins sharply…
FTSE 100 climbs to 10,979 as Bank of England rate hold exposes hawkish tilt
The FTSE 100 touched 10,979 on Thursday morning after the Bank of England rate hold left the index broadly unmoved, yet a shift in voting patterns on the Monetary Policy…
Agilent Q3 earnings beat sends shares to 20-day high
Agilent Q3 earnings beat estimates on revenue and EPS, with China and pharma growth prompting an upgraded full-year forecast.
CrowdStrike raises FY27 guidance after record Q2 ARR growth
CrowdStrike raises full-year guidance after Q2 net new ARR hit $333m, up 51% year-on-year, sending shares up 10.63% on 5 June 2026.
Revolution Medicines Wins FDA Pancreatic Cancer Drug Approval
The FDA's pancreatic cancer drug approval for Revolution Medicines' daraxonrasib lands months early, but the stock barely moved. Here's why.
Majedie Investments NAV Return Tops CPI+4% Target as DCC Bid and Brown Advisory Deal Reshape Quarter
Majedie Investments (MAJE) posted a Majedie Investments NAV return of +10.7% for the quarter to 30 June 2026, beating the trust's CPI-plus-4% annualised objective and lifting the year-to-date NAV return…
Page 41 of 150